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ABSTRACT 
Thirty patients suffering from schizophrenia (diagnosed as per DSM-IV criteria), for more 
than 2 years and having predominant negative symptoms were started on risperidone (2-10 mg/ 
day) and were followed up over a period of 16 weeks. The improvement was assessed using 
PANSS (Positive and Negative Syndrome Scale). 
During this 16 weeks follow up, it was interestingly noted that though there was a significant 
improvement in negative symptoms in all the patients, in 7 patients there was a reemergence of 
positive symptoms. Four patients had increase in rating on suspiciousness and hostility and two 
patients reported auditory hallucinations. One patient developed delusions and conceptual 
disorganization along with suspiciousness and hostility. 
Key words: Risperidone, positive symptoms, schizophrenia. 
In patients suffering from schizophrenia, 
the positive symptoms appear more closely 
related to a hyperdopaminergic state at the 
mesolimbic pathway (Davis et a!., 1991) whereas 
the negative symptoms may be associated with 
hypodopaminergic mesocortical pathway 
(McGlashan & Fenton, 1992; Kibel et al., 1993; 
Peralta & Cuesta, 1996). 
Blockade of D2 receptors by the 
conventional antipsychotics at the mesolimbic 
system seems to effectively control the positive 
symptoms. The blockade of 5HT2 receptors, by 
a typical antipsychotic like clozapine and 
risperidone seems to potentiate dopamine 
release in the prefrontal cortex and enhance the 
dopaminergic neurotransmission at the basal 
ganglia, thereby alleviating negative symptoms 
of schizophrenia and minimizing the 
extrapyramidal symptoms respectively (Kapur 
& Remington, 1996; Love, 1996). 
Research data indicate that Risperidone 
with significant antagonist activity at the 5HT2 
and the D2 receptors may be more effective than 
currently available dopamine antagonists at 
treating both the positive and the negative 
symptoms of schizophrenia (Carman et al., 
1995). 
Number of open and comparative clinical 
trials have explored the efficacy and safety of 
risperidone. These studies have established its 
efficacy in positive as well as negative symptoms 
of schizophrenia and its safety in terms of low 
incidence of extrapyramidal reactions (Claus et 
al., 1992; Chouinard et al., 1993; Ceskov & 
Svestka, 1993; Marder & Meibach, 1994; 
Peuskens, 1995; Agarwal et al., 1998; Bondolfi 
etal ,1998). 
Inspired by this research data, we tried 
risperidone in patients suffering from 
schizophrenia who had predominant negative 
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symptoms and who had shown unsatisfactory 
response to the conventional antipsychotics as 
far as the negative symptoms were concerned. 
MATERIAL & METHOD 
Thirty consecutive patients who satisfied 
following inclusion and exclusion criteria were 
selected for the study. 
Inclusion criteria. Patients satisfying the DSM-
IV criteria for schizophrenia (APA, 1994); having 
total duration of illness at least of 2 years; having 
prior treatment with conventional antipsychotics 
(haloperidol, chlorpromazine, or trifluoperazine) 
and ECTs in adequate dose for at least two years; 
poor response to conventional antipsychotics as 
far as the negative symptoms were concerned; 
predominant negative symptoms at the time of 
inclusion in the study as assessed by negative 
syndrome subscale of PANSS (Positive and 
Negative Syndrome Scale) (Kay et al., 1987). 
Exclusion Criteria: Patients with onset of illness 
after the age of 45 years & comorbidity of 
substance use disorder. 
After the informed consent from the patients 
or their relatives, tablet risperidone was started with 
an initial dose of 1 mg twice daily. The dose was 
increased gradually every week by 2 mg/day till 
maximum of 10 mg/day, based on the clinical 
improvement, tolerance to side effect and 
improvement on negative syndrome subscale of 
PANSS. The conventional antipsychotics were 
gradually discontinued over a period of 1 week 
after starting the patients on risperidone. 
All the patients were regularly assessed 
clinically as well as on PANSS score; initially 
every week for 4 weeks followed by every 2 
weeks for remaining 3 months. 
The collected data was tabulated and 
analysed statistically using paired t-test. 
RESULT AND DISCUSSION 
In the study population of 30 patients, 
there were 15 males and 15 females in the age 
range of 15 to 40 years (mean ±SD 28.67 years 
±8.34). 
During this 16 weeks follow up, it was 
interestingly noted that though there was a 
significant improvement in negative symptoms 
in all the patients, in 7 patients there was a 
reemergence of positive symptoms. 
In the 23 patients there was significant 
improvement in all the subscales of PANSS. A 
substantial more improvement in these patients 
can be noted in the negative symptoms from 
the shift in the positive direction in the composite 
index (the mean of difference between positive 
and negative scores) (Table). 
In contrast to these 23 patients, there was 
significant increase in the mean positive 
subscale score on PANSS for 7 patients in whom 
reemergence of positive symptoms was 
observed (Figure). 
The improvement in negative symptoms 
in these 7 patients was negated by reemergence 
TABLE 
PANSS SCORES BEFORE AND AFTER THE TREATMENT 
PANSS Subscales 
Positive PANSS 
Negative PANSS 
Gen-Psy PANSS 
Composite Index 
N=23 
Before treatment After treatment 
Mean (SD) Mean (SD) 
12.26(6.13) 8.13(2.24) 
t=4.26, p < 0.001 
21.61 (6.46) 9.00 (3.67) 
t=6.93, pO.001 
34.22(11.66) 25.91(9.36) 
t=5.00, p<0.001 
-9.34(11.66) -0.80(3.37) 
t=4.43, p<0.001 
I 
Before treatment After treatment 
Mean (SD) 
8.43(2.15) 
17.43(11.87) 
26.71 (8.12) 
-10.71 (10.19) 
Mean (SD) 
13.43(2.37) 
t=3.59, p < 0.02 
8.86(3.08) 
t=2.51, p<0.05 
27 60(846) 
1=0.19, Not significant 
4.57 (3.78) 
t=3.86, p < 0.01 
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of positive symptoms and so no significant 
change in general psychopathology (Gen-Psy) 
subscale of PANSS was observed. The 
substantial improvement in negative symptoms 
is also reflected in positive shift in composite 
index (Table). 
Out of the 7 patients, 4 patients had 
increase in rating on suspiciousness and hostility 
and two patients reported auditory hallucinations. 
One patient developed delusions and conceptual 
disorganization along with suspiciousness and 
hostility. 
On review of literature we found another 
report by Cung and Stimmel (1997) who have 
also reported the reemergence of positive 
symptoms, especially auditory hallucinations 
after 8 months and again after 24 months of 
risperidone therapy. 
Risperidone's antiserotonergic activity is 
hypothesized to potentiate the dopamine release 
in the prefrontal cortex and enhance 
dopaminergic neurotransmission in the basal 
ganglia, thereby alleviating the negative 
symptoms and minimizing the extrapyramidal 
symptoms (Kapur& Remington, 1996). However, 
a similar potentiation in dopamine release at the 
mesolimbic region may counteract the primary 
antipsychotic activity, resulting in a reemergence 
of positive symptoms. In a recent radioligand 
binding study by Volonte et al. (1997), it has been 
demonstrated that subcutaneous risperidone in 
rates stimulates dopamine release in the medical 
prefrontal cortex, nucleus accumbens and the 
lateral striate cortex to a similar extent. 
The other possibility is that the 
discontinuation of conventional antipsychotics 
may have lead to reemergence of positive 
symptoms in these patients. This is however 
unlikely as risperidone has been reported to be 
useful in negative as well positive symptoms 
(Carmen et al., 1995). 
The probability of inadequate dosage in 
these 7 patients is also unlikely as the mean dose 
of risperidone received by these 7 patients was 
6.9 mg/day which was comparable to the mean 
dose of 6.2 mg/day received by the other 23 
patients who did not develop positive symptoms. 
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